Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations

Cancer Research

Volumn 65, Issue 5, 2005, Pages 1994-2000

  Pohl, Gudrun ^a   Ho, Chung Liang ^a,b   Kurman, Robert J ^a   Bristow, Robert ^a   Wang, Tian Li ^a   Shih, Ie Ming ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CYCLIN D1; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; THROMBOSPONDIN 1; TUMOR NECROSIS FACTOR;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; GENE ACTIVATION; GENE CONTROL; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; GENE TARGETING; GENOTYPE; HUMAN; HUMAN CELL; OVARY TUMOR; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR CELL; VALIDATION PROCESS; WILD TYPE;

APOPTOSIS; BENZAMIDES; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CELL CYCLE; CYCLIN D1; CYSTADENOCARCINOMA, SEROUS; FEMALE; GENE EXPRESSION PROFILING; GENES, RAS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; MUTATION; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS B-RAF; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 16444378374     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3625     Document Type: Article

References (42)

1. Seidman JD, Horkayne-Szakaly I, Haiba M, et al. The histologie type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 2004;23:41-4.
2. Singer G, Oldt R 3rd, Cohen Y, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003;95:484-6.
3. Singer G, Kurman RJ, Chang H-W, et al. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 2002;160:1223-8.
4. Sieben NLG, Macropoulos P, Roemen G, et al. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumors. J Pathol 2004;202:336-40.
5. Ho C-L, Kurman RJ, Dehari R, et al. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res 2004;64:6915-8.
6. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
7. Rajagopalan H, Bardelli A, Lengauer C, et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002;418:934.
8. Singer G, Stohr R, Dehari R, et al. Patterns of p53 mutations separate ovarian serous borderline tumors, low and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis. Am J Surg Pathol. In press 2005.
9. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116:855-67.
10. Olson JM, Hallahan AR. p38 MAP kinase: a convergence point in cancer therapy. Trends Mol Med 2004;10:125-9.
11. Hsu C-Y, Bristow R, Cha M, et al. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas. Clin Cancer Res 2004;10:6432-6.
12. Peyssonnaux C, Eychene A. The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 2001;93:53-62.
13. Allen LF, Sebolt-Leopold J, Meyer MB. CI-1040 (PDI84352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin Oncol 2003;30:105-16.
14. Grill C, Gheyas F, Dayananth P, et al. Analysis of the ERK1,2 transcriptome in mammary epithelial cells. Biochem J 2004;381:635-44.
15. Schaeffer HJ, Weber MJ. Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cell Biol 1999;19:2435-44.
16. Sebolt-Leopold JS, Dudley DT, Herrera R, et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 1999;5:810-6.
17. Sebolt-Leopold JS, Van Becelaere K, Hook K, et al. Biomarker assays for phosphorylated MAP kinase. Their utility for measurement of MEK inhibition. Methods Mol Med 2003;85:31-8.
18. Sebolt-Leopold JS. MEK Inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumors. Curr Pharm Des 2004;10:1907-14.
19. Collisson EA, De A, Suzuki H, et al. Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade. Cancer Res 2003;63:5669-73.
20. Saha S, Sparks AB, Rago C, et al. Using the transcriptome to annotate the genome. Nat Biotechnol 2002;20:508-12.
21. Boyd AC, Charles IG, Keyte JW, et al. Isolation and computer-aided characterization of Mme1, a type II restriction endonuclease from Methylophilus methylotrophus. Nucleic Acids Res 1986;14:5255-74.
22. Buckhaults P, Zhang Z, Chen YC, et al. Identifying tumor origin using a gene expression-based classification map. Cancer Res 2003;63:4144-9.
23. Velculescu VE, Zhang L, Vogelstein B, et al. Serial analysis of gene expression. Science 1995;270:484-7.
24. Lavoie JN, L' Allemain G, Brunet A, et al. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem 1996;271:20608-16.
25. Balmanno K, Cook SJ. Sustained MAP kinase activation is required for the expression of cyclin D1, p21Cip1 and a subset of AP-1 proteins in CCL39 cells. Oncogene 1999;18:3085-97.
26. Arteaga CL, Baselga J. Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them? Cancer Cell 2004;5:525-31.
27. Bristow RE, Gossett DR, Shook DR, et al. Micropapillary serous ovarian carcinoma: surgical management and clinical outcome. Gynecol Oncol 2002;86:163-70.
28. Bristow RE, Gossett DR, Shook DR, et al. Recurrent micropapillary serous ovarian carcinoma. Cancer 2002;95:791-800.
29. 1-phase progression. Genes Dev 1999;13:1501-12.
30. Sherr CJ. Cell cycle control and cancer. Harvey Lect 2000;96:73-92.
31. Worsley SD, Ponder BA, Davies BR. Overexpression of cyclin D1 in epithelial ovarian cancers. Gynecol Oncol 1997;64:189-95.
32. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-82.
33. Schneider P, Thome M, Burns K, et al. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-κB. Immunity 1997;7:831-6.
34. Pan G, O'Rourke K, Chinnaiyan AM, et al. The receptor for the cytotoxic ligand TRAIL. Science 1997;276:111-3.
35. Ye Q, Hu YF, Zhong H, et al. BRCA1-induced large-scale chromatin unfolding and allele-specific effects of cancer-predisposing mutations. J Cell Biol 2001;155:911-21.
36. Watnick RS, Cheng YN, Rangarajan A, et al. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell 2003;3:219-31.
37. Rodriguez-Manzaneque JC, Lane TF, Ortega MA, et al. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci U S A 2001;98:12485-90.
38. Dawson DW, Pearce SF, Zhong R, et al. CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 1997;138:707-17.
39. Bleuel K, Popp S, Fusenig NE, et al. Tumor suppression in human skin carcinoma cells by chromosome 15 transfer or thrombospondin-1 overexpression through halted tumor vascularization. Proc Natl Acad Sci U S A 1999;96:2065-70.
40. Streit M, Velasco P, Brown LF, et al. Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. Am J Pathol 1999;155:441-52.
41. Volpert OV, Pili R, Sikder HA, et al. Id1 regulates angiogenesis through transcriptional repression of thrombospondin-1. Cancer Cell 2002;2:473-83.
42. Griffin M, Casadio R, Bergamini CM. Transglutaminases: nature's biological glues. Biochem J 2002;368:377-96.